Future Drug Treatments for Type 2 Diabetes

Bailey, Clifford J.

doi:10.1002/9781118924853.ch67

Cited by 2 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few developing pharmacological avenues that may either act directly on or significantly influence glucosemediated amplification are highlighted in this section. For in-depth information pertaining to novel treatments for type 2 diabetes targeted across multiple tissues, please see (Bailey, 2017;Scheen, 2016).…”

Section: β Cell Therapeuticsmentioning

confidence: 99%

Mechanisms of the amplifying pathway of insulin secretion in the β cell

Kalwat

Cobb

2017

Pharmacology & Therapeutics

113

View full text Add to dashboard Cite

Pancreatic islet β cells secrete insulin in response to nutrient secretagogues, like glucose, dependent on calcium influx and nutrient metabolism. One of the most intriguing qualities of β cells is their ability to use metabolism to amplify the amount of secreted insulin independent of further alterations in intracellular calcium. Many years studying this amplifying process have shaped our current understanding of β cell stimulus-secretion coupling; yet, the exact mechanisms of amplification have been elusive. Recent studies utilizing metabolomics, computational modeling, and animal models have progressed our understanding of the metabolic amplifying pathway of insulin secretion from the β cell. New approaches will be discussed which offer in-roads to a more complete model of β cell function. The development of β cell therapeutics may be aided by such a model, facilitating the targeting of aspects of the metabolic amplifying pathway which are unique to the β cell.

show abstract

Section: β Cell Therapeuticsmentioning

confidence: 99%

Mechanisms of the amplifying pathway of insulin secretion in the β cell

Kalwat

Cobb

2017

Pharmacology & Therapeutics

113

View full text Add to dashboard Cite

show abstract

“…One of the most important enzymes involved in GCs activity is 11b-hydroxysteroid dehydrogenase 1 (11b-HSD1), which converts cortisone to cortisol, the primary GC in humans, mostly in liver and adipose tissue, so that the inhibition of this enzyme could reduce cortisol production within these tissues without substantially affecting circulating cortisol (Anderson and Walker 2013). This is the reason why 11b-HSD1 has been proposed as an innovative therapeutic target for the treatment of Type 2 DM (Bailey et al 2016;Bailey 2017). There are many pharmaceutical companies working very actively in this area, developing many different chemical structures displaying inhibition of 11b-HSD1 (Scott et al 2014); many of these chemical structures present stereogenic centres, and thus they could be synthesized with the help of biocatalysis.…”

mentioning

confidence: 99%

Biocatalyzed synthesis of antidiabetic drugs: A review

Alcántara

2017

Biocatalysis and Biotransformation

View full text Add to dashboard Cite

Future Drug Treatments for Type 2 Diabetes

Cited by 2 publications

References 80 publications

Mechanisms of the amplifying pathway of insulin secretion in the β cell

Mechanisms of the amplifying pathway of insulin secretion in the β cell

Biocatalyzed synthesis of antidiabetic drugs: A review

Contact Info

Product

Resources

About